COVID-19 Mortality Rate in Nine High-income Metropolitan Regions
Overview
Authors
Affiliations
We analyzed the spread of the COVID-19 epidemic in 9 metropolitan regions of the world with similar socio-demographic characteristics, daytime commuting population and business activities: the New York State, Bruxelles-Capital, the Community of Madrid, Catalonia, the Île-de-France Region, the Greater London county, Stockholms län, Hovedstaden (Copenhagen) and the Lombardy Region. The Lombardy region reported the highest COVID-19 crude mortality rate (141.0 x 100,000) 70-days after the onset of the epidemic, followed by the Community of Madrid (132.8 x 100,000) New York State (120.7 x 100,000). The large variation in COVID-19 mortality and case-fatality rates for COVID-19 in different age strata suggested a more accurate analysis and interpretation of the epidemic dynamics after standardization of the rates by age. The share of elder populations (>70 years) over total population varies widely in the considered study settings, ranging from 6.9% in Catalonia to 17.0% in Lombardy. When taking age distribution into consideration the highest standardized mortality rate was observed in the State of New York (257.9 x 100,000); with figures in most of the European regions concentrated between 123.3 x 100,000 in Greater London and 177.7 x 100,000 in Bruxelles-Capital, lower in French and Danish regions. We also report and critical appraise, when available, COVID-19 mortality figures in capital cities, nursing homes, as well as excess mortality at country level. Our data raise awareness on the need for a more in-depth epidemiological analysis of the current COVID-19 public health emergency that further explores COVID-19 mortality determinants associated with health services delivery, community-level healthcare, testing approaches and characteristics of surveillance systems, including classification of COVID-19 deaths.
Anderson D, DeCaro R, Chadalavada M, Marin A, Di Crosta A, Ceccato I J Aging Environ. 2024; 2023:1-37.
PMID: 39055175 PMC: 11271746. DOI: 10.1080/26892618.2023.2269552.
Abifadel M, Ahmmed K, Banu S, Camara I, Chowdhury F, Coulibaly D Am J Trop Med Hyg. 2024; 110(4):741-748.
PMID: 38412531 PMC: 10993839. DOI: 10.4269/ajtmh.23-0456.
Aldossari H, Salam A Front Public Health. 2024; 12:1281289.
PMID: 38299074 PMC: 10829572. DOI: 10.3389/fpubh.2024.1281289.
Blandi L, Sabbatucci M, Dallagiacoma G, Alberti F, Bertuccio P, Odone A Vaccines (Basel). 2022; 10(11).
PMID: 36366331 PMC: 9696549. DOI: 10.3390/vaccines10111822.
Mauer N, Chiecca G, Carioli G, Gianfredi V, Iacoviello L, Bertagnolio S Int J Public Health. 2022; 67:1604427.
PMID: 35645700 PMC: 9131487. DOI: 10.3389/ijph.2022.1604427.